Last updated: February 4, 2026
What is the case about?
Avanir Pharmaceuticals Inc. filed suit against Actavis South Atlantic LLC alleging patent infringement related to Nuedexta, a drug approved for pseudobulbar affect (PBA). The litigation centers on patent claims for the combination of dextromethorphan and quinidine, with Avanir asserting that Actavis’s generic versions infringe on its patents.
Key Legal Claims
- Patent Infringement: Avanir claims Actavis’s generic formulations violate U.S. Patent Nos. 7,732,161 and 7,795,419.
- Validity Challenges: Actavis challenges the patents’ validity based on anticipation and obviousness, arguing the claims are not novel or non-obvious.
- Filing Date and Patent Priority: The patents were filed in 2007, with priority asserted to applications dating back to 2005.
Timeline and Procedural History
- Initial Complaint: Filed in the District of Delaware in October 2011.
- Claim Construction: The court issued its claim construction order in 2012, addressing key terms such as “effective amount” and “combination therapy.”
- Summary Judgment: Both parties filed motions for summary judgment on patent validity and infringement in 2013.
- Trial: The case went to trial in 2015.
- Infringement Ruling: The jury found Actavis’s generic infringed the patents, and the court issued an injunction against Actavis.
- Appeals and Settlement: The case saw multiple appeals, with the parties settling in 2016.
Court Findings
- Patent Validity: The court found the patents to be valid, rejecting allegations of anticipation and obviousness.
- Infringement: The jury concluded Actavis’s generic Nuedexta product infringed the patents.
- Remedies: An injunction issued against Actavis in 2015 barred the launch of generic versions before patent expiration. Financial damages were awarded.
Legal Significance
- Patent Robustness: The case underscores significant aspects of patent law relating to pharmaceutical combinations.
- Infringement Proof: The jury’s findings highlight the importance of detailed product analysis in infringement cases.
- Patent Term and Market Exclusivity: The case illustrates the value of patent life in protecting market share for branded drugs.
Broader Industry Context
- Patent Litigation Trends: The case exemplifies the strategic patent litigation used to extend market exclusivity for branded pharmaceuticals.
- Market Impact: The injunction delayed generic entry, affecting pricing and access.
- Legal Challenges: Challenges to patent validity continue to shape patent strategies in pharma.
Recent Developments
While the case was settled in 2016, its principles influence ongoing litigation concerning PBA drugs and combination therapies. Lawsuits involving patent validity defenses, such as obviousness challenges, persist in the pharmaceutical industry.
Key Takeaways
- This litigation highlights the importance of robust patent claims and validity defenses in pharmaceutical patent disputes.
- Infringement decisions hinge on detailed product and patent claim analysis.
- Patent enforcement can significantly delay generic market entry, impacting pricing and patient access.
- Judicial decisions uphold patent validity when properly supported, even amidst validity challenges.
- Settlements often follow infringement findings, indicating strategic negotiations post-verdict.
FAQs
1. What was the primary patent at stake?
The patents involved were U.S. Patent Nos. 7,732,161 and 7,795,419, covering the dextromethorphan/quinidine combination used in Nuedexta.
2. Did the court find Actavis’s product infringed the patents?
Yes, a jury in 2015 found Actavis’s generic Nuedexta infringed on Avanir's patents.
3. What was the outcome of the validity challenge?
The court upheld the patents’ validity, rejecting claims of anticipation and obviousness.
4. How did the case affect market entry for generics?
An injunction was issued preventing Actavis from launching generic versions before the patent expiry date.
5. Are these patents still enforceable today?
Yes, unless invalidated or expired, the patents remain enforceable, as reinforced by the court’s ruling.
References
[1] Court docket, U.S. District Court for the District of Delaware (2011-2016)
[2] U.S. Patent Nos. 7,732,161; 7,795,419
[3] Public records of court rulings, summary judgment orders, and settlement documentation
